Learn more about us
Translational research group in uveal melanoma
Why have we created this group?
Cancer is the leading cause of death in Europe, which is why the early diagnosis, accurate prognosis, and treatment of this disease are among the main goals of medicine. We believe these goals can be achieved through translational research, by developing new biomarkers and exploring novel treatments that complement or improve existing ones.
Uveal melanoma is a rare type of eye cancer that originates in the vascular layer of the eye called the uvea. This layer is comprised of the choroid, the ciliary body, and the iris. A diagnosis of uveal melanoma is serious because approximately half of patients will develop metastatic disease, most commonly in the liver, which is a common cause of death among these patients.
We created this research group to study the molecular mechanisms that give rise to the tumour followed by dissemination (metastasis) of the tumour cells. We are also exploring new diagnostic and therapeutic modalities to improve survival rates.
What do we do?
Barcelona Uveal Melanoma is a team of professionals from Bellvitge University Hospital (HUB), Bellvitge Biomedical Research Institute (IDIBELL), and the Catalan Institute of Oncology (ICO – L’Hospitalet). Biologists, oncologists, pathologists, and ophthalmologists all work together to improve the care of patients with uveal melanoma.
We created a pioneering Ocular Oncology Unit, which has been designated as a reference centre (CSUR) in the Spanish National Health Care System. We are recognized by the European Union as a center of expertise for the management of uveal melanoma through the Orphanet platform. We also form part of the European adult cancer network known as ERN-EURACAN.
Our research team was accredited in 2017 by the Catalan government (Generalitat de Catalunya; AGAUR) as an emerging research group.